Logo image
Back
Beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, attenuates anxiety-related behavior in a rodent post-traumatic stress disorder model
Journal article   Open access   Peer reviewed

Beta-hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, attenuates anxiety-related behavior in a rodent post-traumatic stress disorder model

Takehiko Yamanashi, Masaaki Iwata, Midori Shibushita, Kyohei Tsunetomi, Mayu Nagata, Naofumi Kajitani, Akihiko Miura, Ryoichi Matsuo, Tsuyoshi Nishiguchi, Takahiro A Kato, …
Scientific reports, Vol.10(1), pp.21629-21629
12/10/2020
DOI: 10.1038/s41598-020-78410-2
PMCID: PMC7728809
PMID: 33303808
url
https://doi.org/10.1038/s41598-020-78410-2View
Published (Version of record) Open Access

Abstract

Accumulating evidence suggests that elevated inflammation contributes to the pathophysiology of post-traumatic stress disorder (PTSD) and that anti-inflammatory drugs might be a new treatment strategy for PTSD. It has been reported that beta-hydroxybutyrate (BHB), one of the main ketone bodies produced, can have an anti-inflammatory and antidepressant effect. Here, we investigated the potential anti-anxiety and anti-inflammatory effects of BHB using a rodent PTSD model, induced by single prolonged stress (SPS). Male, Sprague–Dawley rats were employed in this study. Repeated administration of BHB attenuated SPS-induced anxiety-related behaviors evaluated by the elevated plus maze test. SPS increased the serum levels of TNF-α and IL-1β. In contrast, BHB administration partially attenuated the increase of serum TNF-α. These findings demonstrate that BHB exerts its anxiolytic effects, possibly by inhibiting systemic TNF-α. Hence, BHB may be a novel therapeutic candidate for the treatment of PTSD.
 Neuroimmunology Post-traumatic stress disorder

Details

Metrics

33 Record Views
32 Times Cited - Web of Science
Logo image